AMG 337: Clinical Trials

6 trials of AMG 337, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 2 withdrawn. 5 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Terminated 2, Withdrawn 2, Completed 1
Phase 13Completed 2, Withdrawn 1

Follow AMG 337: new trials by email Literature Review of AMG 337 trials Research Report on AMG 337

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
AMG 337 - Clear Cell Sarcoma
Phase 2TerminatedNantPharma, LLC82018-08-292024-05-24
QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors
AMG 337 - Solid Tumor
Phase 2WithdrawnNantPharma, LLC2018-05-022019-08-28
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Phase 1 / Phase 2WithdrawnEastern Cooperative Oncology Group2015-03-062023-05-25
A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects
AMG 337 - Stomach Neoplasms
Phase 1 / Phase 2CompletedAmgen112014-04-152021-12-28
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
AMG 337 - Stomach Neoplasms
Phase 2TerminatedAmgen602014-02-012017-07-02
A Study of AMG 337 in Subjects With Advanced Solid Tumors
AMG 337 - Advanced Malignancy, Advanced Solid Tumors
Phase 1CompletedAmgen1112010-12-082022-11-07

Conditions studied

Stomach Neoplasms (3)  ·  Adenocarcinoma Of Esophagus (2)  ·  Esophageal Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Neoplasms (1)  ·  Sarcoma, Clear Cell (1)

Sponsors

Amgen (3)  ·  NantPharma, LLC (2)  ·  Eastern Cooperative Oncology Group (1)

Countries

United States (5)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Chile (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Italy (1)  ·  Japan (1)  ·  Peru (1)  ·  Poland (1)

Top investigators

Lakshmi Rajdev (1)

NIH funding

U10CA180820 (1)